PMEL and melanoma: Although early studies showed that MART-1 and gp100 are among the major tumor antigens recognized by anti-melanoma TIL, recent advances in whole-exome sequencing offer the potential to reveal novel antigens (i.e. neoantigens) resulting from mutations that may be highly immunogenic but also safe due to their absence from the rest of the body (50).